Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses: 2014-2025

Historic Operating Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $110.6 million.

  • Viridian Therapeutics, Inc.\DE's Operating Expenses rose 32.33% to $110.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $398.9 million, marking a year-over-year increase of 40.79%. This contributed to the annual value of $299.3 million for FY2024, which is 17.50% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Operating Expenses is $110.6 million, which was up 3.50% from $106.8 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Expenses registered a high of $110.6 million during Q3 2025, and its lowest value of $14.3 million during Q3 2021.
  • Its 3-year average for Operating Expenses is $78.7 million, with a median of $72.6 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Operating Expenses was 191.78% (2021), while the steepest drop was 67.68% (2021).
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Expenses (Quarterly) stood at $29.3 million in 2021, then skyrocketed by 67.85% to $49.2 million in 2022, then skyrocketed by 45.51% to $71.5 million in 2023, then increased by 22.35% to $87.5 million in 2024, then skyrocketed by 32.33% to $110.6 million in 2025.
  • Its Operating Expenses was $110.6 million in Q3 2025, compared to $106.8 million in Q2 2025 and $93.9 million in Q1 2025.